Clinical trial NCT04923750: Detection of Acute Renal Failure Using Hospital Coding Data
Official title: Acute Kidney Injury and Drug-related Acute Kidney Injury : Use of Hospital Coding Data for Their Identification
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Renal Failure
Iatrogenic Effect
Uremic Toxin
Keywords: acute renal failure
iatrogenic
pharmaco epidemiology
medico economy
Uremic toxin
PMSI
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2021-06-11
Enrollment: 498
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized at the CHU Amiens Picardie during 6 months and for which at least two plasma creatinine measurements were taken during the hospitalization

Brief summary: AKI is a rapid and usually reversible impairment of kidney function that is life-threatening in the short term well described by the "Kidney Disease: Improving Global Outcomes - KDIGO" classification of 2012. Whatever etiology of acute renal failure, drug iatrogeny still has its place. Hospital data from the information systems medicalization program (PMSI) can be used for epidemiological research. No study has yet been performed on these data to assess drug-related AKI. However, it should be remembered that these databases were not originally designed for research purposes but for reimbursement of care. Therefore, before conducting a large-scale study, it remains important to determine the validity and representativeness of the codes used for coding the studied events. The objective of this project is therefore to validate the use of hospital coding to identify AKI.

Detailed description: Acute kidney injury (AKI) is a rapid and usually reversible impairment of kidney function that is life-threatening in the short term; the grades of which are defined by the KDIGO classification of 2012. Whatever etiology of acute renal failure, drug iatrogeny still has its place. Data literature indicate that AKI affects more than one in five adults worldwide while hospitalized, with an associated mortality rate above 20%. It constitutes a non-negligible part of hospitalizations when it is acquired in the community, and also causes prolongations of hospitalizations, and therefore an increase in the cost for the hospital. Hospital data from the information systems medicalization program (PMSI) is a device that is part of the reform of the French health system with the aim of reducing inequalities in resources between health establishments. Since 2007, it has been possible to link all discharge summaries for one patient. The diagnoses identified during hospitalization are coded according to the 10th edition of the International Classification of Diseases (ICD-10). The data from PMSI coding can be used for epidemiological research. The majority of studies were related to patients with chronic kidney disease, especially dialysis patients. No study has yet been performed on these data to assess drug-related AKI. However, it should be remembered that these databases were not originally designed for research purposes but for reimbursement of care. Therefore, before conducting a large-scale study, it remains important to determine the validity and representativeness of the codes used for coding the events to be studied.

Eligibility criteria: Inclusion Criteria:

* Patients over \> = 18 years old
* Patients hospitalized at the CHU Amiens Picardie during 6 months
* patients for which at least two plasma creatinine measurements were taken during the hospitalization

Exclusion Criteria:

* Patients under \<18 years old
* Patients on dialysis for chronic renal failure
* Hospitalization for a kidney transplant
* Postpartum AKI

Primary outcomes:
measure: identification of AKIs by codes in the PMSI database
timeFrame: two years
measure: identification of drug-induced AKIs by codes in the PMSI database
timeFrame: two years
Secondary outcomes:
measure: Variation of performance of the codes according to the characteristics of the AKI
timeFrame: two years
measure: Variation of performance of the codes according to KDIGO grade
timeFrame: two years
measure: Variation of performance of the codes according to hospitalization service
timeFrame: two years
measure: Identification of the type of drugs involved in drug-induced AKI
timeFrame: two years
measure: incidence of drug-induced AKI
timeFrame: two years
measure: Identification of AKI Risk factors
timeFrame: two years
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens
Study officials:
References: